

NTUH Becomes a Partner in the Quintiles “Prime Site Program”

New drug development has always been the priority for the national biotechnology industry in Taiwan. Cooperation with top drug-development partners in the world is a proactive way to achieve this goal. On December 14, 2011, NTUH signed an agreement with U.S.-based pharmaceutical services provider, Quintiles, to become a partner in the Prime Site Program. NTUH's Superintendent, Prof. Ming-Fong Chen, and Mr. Michael Klein, Vice President of Clinical Development, Quintiles Asia Site Services, represented each respective party to sign the agreement. Under the agreement, the two parties will cooperate on the development and clinical trials of new drugs, as well as the devotion to improve human health and longevity.

Quintiles' “Prime Site Program” seeks cooperation with the best medical centers in the world for groundbreaking drug development and accelerated research process, in order to satisfy patients' urgent need for treatment. NTUH is selected by Quintiles for its renowned excellence in research, and it is the first hospital in Taiwan to participate in the “Prime Site Program”.

Through this program, NTUH and Quintiles will strive to improve the wellbeing of all patients, and to reach new milestones in biotechnology research and development in Taiwan and in the whole world.



Above : NTUH Signs “Prime Site Program” with Quintiles

- ◆ Source : IMSC
- ◆ Release Date : December, 2011

- ◆ Excerptor: IMSC
- ◆ Excerpted on: January 9th, 2012